Opinion|Videos|March 4, 2025
Future Treatment Considerations for Multiple Myeloma
Panelists discuss how they approach sequencing therapy for relapsed/refractory multiple myeloma, considering all approved and investigational agents, and the factors that guide their treatment choices. They also explore the future directions of the later-stage relapsed/refractory multiple myeloma space, time permitting.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Considering all the agents (approved and in development), how do you approach sequencing therapy?
- How would you choose? What are the factors you consider?
- Where is the later-stage R/R MM space headed (time permitting)?
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA received a BLA for etentamig in relapsed/refractory multiple myeloma, based on response and PFS gains in the phase 3 CERVINO trial.
Elranatamab improved PFS vs 3 standard regimens in relapsed/refractory multiple myeloma in the phase 3 MagnetisMM-32 trial.
The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.
Advertisement
Advertisement
Trending on OncLive
1
RELATIVITY-1093 Trial Aims to Advance Nivolumab Plus Relatlimab and Chemo in Nonsquamous NSCLC
2
Dostarlimab Monotherapy Elicits Durable cCRs in dMMR/MSI-H Locally Advanced Rectal Cancer
3
NEXERA-303 Trial Aims to Bring TGFβR2×PD-1 Bispecific Antibody INCA33890 Into First-Line MSS CRC
4
The OncFive: Top Oncology Articles for the Week of 10/25
5